ADC Therapeutics WKN: A2PSR8 ISIN: CH0499880968 Kürzel: ADCT Forum: Aktien Thema: Hauptdiskussion

Ratings der Analysten: ADCT has been the topic of a number of analyst reports. Stephens boosted their price objective on shares of ADC Therapeutics from $6.00 to $8.00 and gave the company an "overweight" rating in a research report on Monday, February 24th. Guggenheim reduced their price target on ADC Therapeutics from $10.00 to $7.00 and set a "buy" rating on the stock in a report on Monday, March 31st. Cantor Fitzgerald reiterated an "overweight" rating on shares of ADC Therapeutics in a report on Friday, March 7th. Finally, HC Wainwright reissued a "buy" rating and set a $8.00 target price on shares of ADC Therapeutics in a research note on Monday, March 31st. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, ADC Therapeutics presently has an average rating of "Buy" and a consensus target price of $7.75.